CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
CASI Pharma Raises $48.5 Million to Acquire New Drugs - NAI 500
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol | World Pharma Today
CASI Insider Trading Activity - CASI Pharmaceuticals, Inc.
CASI -- Is Its Stock Price A Worthy Investment? Learn More.
CASI Pharmaceuticals Inc Share Price USD0.0001
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd -December 08, 2023 at 04:06 pm EST | MarketScreener
CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular Lymphoma | BioBuzz
CASI Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:CASI) | Seeking Alpha
CASI-CASI Pharmaceuticals
CASI Pharmaceuticals Culture | Comparably
CASI Pharmaceuticals, Inc.
tm234270d2_f4sp4img001.jpg
1JsfgvuJpT-kMC764BVYw2Jm585pw2mWQ.png?v=1701794727
CASI Pharmaceuticals, Inc. (CASI) Company Profile & Overview - Stock Analysis
CASI Pharmaceuticals to Report Third Quarter 2023 Financial Results-Upcoming Events-CASI
CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment - NAI 500
CASI PHARMACEUTICALS INC.
CASI Acquires Rights To Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 | Contract Pharma
CASI Pharmaceuticals – executive interview - YouTube
Mission Statement, Vision, & Core Values (2024) of CASI Pharmaceuticals, Inc. (CASI)
CASI Pharmaceuticals Raises $21 Million | citybiz
Alert: Major Price Advance (8/10/22)-CASI Pharmaceuticals Inc (NASDAQ: CASI). - PriceTarget Research
CASI Pharmaceuticals, Inc. (NASD:CASI) Seasonal Chart | Equity Clock
BioInvent and CASI on their collaboration - BioStock
